Protalex, Inc. (PRTX) Announces Acceptance Of Abstract Highlighting Findings From U.S. Phase 1(B) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients At The 2014 American College of Rheumatology Annual Meeting
9/3/2014 9:01:22 AM
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was accepted for poster presentation at the upcoming American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting 2014 being held in Boston, Massachusetts from November 14-19, 2014. The abstract will be available at the ACR’s website at http://www.acrannualmeeting.org and on the Company’s website at www.protalex.com.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by